|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date20 Jun 2022 |
一项TAS-116(pimitespib)联合伊马替尼治疗晚期胃肠道间质瘤患者的Ⅰ期研究
[Translation] A phase I study of TAS-116 (pimitespib) combined with imatinib in patients with advanced gastrointestinal stromal tumors
这是一项I期、开放性、多国、多中心研究。
在中国患者剂量递增部分,将在中国患者中评估pimitespib单药治疗以及与伊马替尼联合治疗的安全性和耐受性。
[Translation] This is a phase I, open-label, multinational, multicenter study.
In the dose-escalation part of Chinese patients, the safety and tolerability of pimitespib monotherapy and combination therapy with imatinib will be evaluated in Chinese patients.
100 Clinical Results associated with Dapeng Drug Information Consulting (Beijing) Co., Ltd.
0 Patents (Medical) associated with Dapeng Drug Information Consulting (Beijing) Co., Ltd.
100 Deals associated with Dapeng Drug Information Consulting (Beijing) Co., Ltd.
100 Translational Medicine associated with Dapeng Drug Information Consulting (Beijing) Co., Ltd.